OrforglipronEli LillyInsurance Coverage Outlook

Formulary Tier

Expected: Tier 3 or Tier 4
Based on Rybelsus (Tier 3 on most plans) and other GLP-1s. Higher tiers mean higher copays (typically $50–$150 for Tier 3, $100–$500 for Tier 4).

Prior Authorization

Expected: Required
You'll need your doctor to submit clinical documentation proving medical necessity, including BMI, comorbidities, and evidence of prior lifestyle interventions.

Step Therapy

Possible
Some plans may require trying metformin, phentermine, or other weight-loss medications first. This can delay access by 3-6 months if you must document "failure" of prior treatments.

Medical Necessity Criteria

Expected Requirements:
• BMI ≥30 OR BMI ≥27 with comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea)
• Documentation of 6-12 months of lifestyle modification
• No contraindications (history of pancreatitis, MEN2, medullary thyroid cancer)

Type 2 Diabetes Indication

Likely Covered
If orforglipron receives FDA approval for type 2 diabetes, it may be covered under Medicare Part D, as Ozempic, Mounjaro and Rybelsus can be, subject to the plan's formulary, prior authorization and exceptions process. Copays vary by plan but count toward the Part D out-of-pocket cap: $2,100 in 2026 ($2,400 in 2027).

Obesity Indication (New Policy)

Covered Through the Medicare GLP-1 Bridge
The Bridge (July 1, 2026 – December 31, 2027) covers Foundayo for weight loss for $50 per monthly fill if you meet one of CMS's eligibility tiers: Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD.

Cardiovascular Indication

Covered if Approved
Wegovy may be covered under Medicare Part D to reduce cardiovascular risk (adults with established cardiovascular disease and either obesity or overweight), subject to the plan's formulary and prior authorization. If orforglipron receives a similar cardiovascular indication, Part D coverage for that use could follow.

Important Limitation

Not All Medicare Beneficiaries Qualify
Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026. If you don't meet the Bridge criteria, basic Part D coverage excludes Foundayo when used for weight loss.

States with GLP-1 Coverage

13 states (as of January 2026)
These state Medicaid programs covered GLP-1s for obesity treatment (per KFF). States change often: check your own state. Coverage typically requires prior authorization and participation in a comprehensive weight-loss program.

States Without Coverage

Many States Exclude Obesity Drugs
Many state Medicaid programs still classify obesity medications as "cosmetic" or "lifestyle" and exclude them from coverage, even when medically necessary. This may change as evidence for metabolic benefits grows.

Prior Authorization Requirements

Typically Required
States that cover GLP-1s usually require:
• BMI ≥30 (or ≥27 with comorbidity)
• 6-12 months documented weight-loss attempts
• Participation in behavioral weight-loss program
• Regular follow-up visits

How to Check Your State

Action Steps:
1. Visit your state Medicaid website
2. Search for "Preferred Drug List" or "Formulary"
3. Look under "Endocrine" or "Weight Loss" categories
4. Check if GLP-1 receptor agonists are listed
5. Review prior authorization criteria

What It Is: Prior authorization requires your doctor to submit clinical documentation to your insurance company before they'll approve coverage. The insurer reviews your medical history, BMI, comorbidities, and prior treatments to determine if the medication is "medically necessary."

Why It Exists: Insurers use PA to control costs and ensure medications are used appropriately. For expensive medications like GLP-1s, PA helps prevent off-label use and ensures patients meet clinical criteria.

How to Overcome:

• Work with your doctor to submit a complete PA form with all required documentation
• Include a detailed letter of medical necessity explaining why orforglipron is appropriate for you
• Document your BMI, weight-related comorbidities, and prior weight-loss attempts
• If denied, appeal immediately with additional supporting evidence
• Consider using Honest Care's appeal service to improve approval chances

What It Is: Step therapy requires you to try and fail less expensive treatments before your insurer will approve a more expensive medication like orforglipron. This might mean trying metformin, phentermine, or lifestyle programs first.

Why It Exists: Step therapy controls costs by ensuring patients start with lower-cost interventions. If those work, expensive medications aren't needed. If they don't, the insurer has documentation justifying the upgrade.

How to Overcome:

• Document prior treatment failures thoroughly (medications tried, duration, outcomes)
• Request a step therapy exception if you have contraindications to required first-line drugs
• Demonstrate medical urgency (e.g., severe obesity with rapidly progressing comorbidities)
• Work with your doctor to show why orforglipron is uniquely appropriate (e.g., no-fasting convenience aids adherence)

What It Is: Quantity limits restrict how much medication you can receive per fill (e.g., 30-day supply only, no 90-day fills). This forces more frequent refills and pharmacy visits.

Why It Exists: Insurers use quantity limits to monitor high-cost medication use and reduce waste. For GLP-1s, limits also ensure patients are actively using the medication and attending follow-up visits.

How to Overcome:

• Request a quantity limit override if 30-day supplies are inconvenient or you travel frequently
• Use mail-order or specialty pharmacies that may allow 90-day supplies
• Set up automatic refills to avoid lapses in coverage

What It Is: Some plans completely exclude certain medications from coverage, meaning no amount of appeals or documentation will result in approval. This is becoming more common for weight-loss drugs as costs rise.

Why It Exists: Employers and insurers may exclude entire drug classes (like obesity medications) to control costs, especially if they consider obesity a "lifestyle" condition rather than a medical disease.

How to Overcome:

• Check your plan's formulary BEFORE orforglipron launches to confirm it's not excluded
• If excluded, appeal to your employer's HR department for formulary changes during annual enrollment
• Consider switching plans during open enrollment if your current plan excludes obesity medications
• Explore manufacturer savings programs or patient assistance programs if insurance won't cover
• If you have a medically necessary indication (e.g., prediabetes, cardiovascular risk), emphasize those in appeals rather than weight loss alone